NASDAQ:UTHR - United Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $206.86
  • Forecasted Upside: 23.03 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$168.14
▼ -0.66 (-0.39%)
1 month | 3 months | 12 months
Get New United Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for UTHR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for UTHR

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$206.86
▲ +23.03% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for United Therapeutics in the last 3 months. The average price target is $206.86, with a high forecast of $275.00 and a low forecast of $123.00. The average price target represents a 23.03% upside from the last price of $168.14.
Buy
The current consensus among 8 polled investment analysts is to buy stock in United Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 1 sell ratings
9/5/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 2 sell ratings
12/4/2019
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
3/3/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 1 sell ratings
6/1/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 1 sell ratings
8/30/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 1 sell ratings
11/28/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/25/2021WedbushBoost Price TargetOutperform$255.00 ➝ $260.00Low
i
2/22/2021Credit Suisse GroupBoost Price TargetOutperform$169.00 ➝ $196.00Low
i
2/16/2021OppenheimerBoost Price TargetOutperform$200.00 ➝ $275.00Low
i
2/1/2021HC WainwrightUpgradeNeutral ➝ Buy$125.00 ➝ $195.00Low
i
Rating by A. Fein at HC Wainwright
1/20/2021OppenheimerBoost Price TargetOutperform$175.00 ➝ $200.00Low
i
1/20/2021CowenBoost Price TargetOutperform$160.00 ➝ $200.00Low
i
1/20/2021LADENBURG THALM/SH SHBoost Price TargetPositive ➝ Buy$151.00 ➝ $199.00Low
i
10/29/2020WedbushBoost Price TargetOutperform$247.00 ➝ $255.00Low
i
Rating by Liana Moussatos at Wedbush
10/29/2020OppenheimerBoost Price TargetOutperform$165.00 ➝ $175.00Medium
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
9/14/2020JPMorgan Chase & Co.Initiated CoverageOverweightHigh
i
7/30/2020OppenheimerBoost Price TargetOutperform$155.00 ➝ $165.00Low
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
7/29/2020WedbushReiterated RatingBuy$243.00 ➝ $244.00Low
i
Rating by Liana Moussatos at Wedbush
6/25/2020WedbushReiterated RatingBuy$243.00High
i
Rating by Liana Moussatos at Wedbush
6/25/2020Credit Suisse GroupBoost Price TargetOutperform$129.00 ➝ $145.00Medium
i
6/25/2020HC WainwrightBoost Price TargetNeutral$85.00 ➝ $125.00Medium
i
6/24/2020OppenheimerInitiated CoverageBuy$155.00Medium
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
6/17/2020WedbushReiterated RatingBuy$243.00High
i
Rating by Liana Moussatos at Wedbush
6/12/2020CowenReiterated RatingBuy$145.00Medium
i
Rating by Chris Shibutani at Cowen Inc
4/30/2020WedbushReiterated RatingBuy$243.00Low
i
Rating by Liana Moussatos at Wedbush
4/30/2020Credit Suisse GroupReiterated RatingBuyLow
i
Rating by Martin Auster at Credit Suisse Group AG
3/10/2020Jefferies Financial GroupUpgradeHold ➝ Buy$115.00 ➝ $123.00High
i
3/4/2020WedbushReiterated RatingBuy$243.00Low
i
Rating by Liana Moussatos at Wedbush
2/27/2020CowenUpgradeMarket Perform ➝ Outperform$119.00 ➝ $145.00High
i
Rating by Chris Shibutani at Cowen Inc
2/24/2020WedbushReiterated RatingOutperform ➝ Buy$237.00 ➝ $243.00High
i
Rating by Liana Moussatos at Wedbush
2/13/2020Credit Suisse GroupBoost Price TargetOutperform$113.00 ➝ $121.00Low
i
Rating by Martin Auster at Credit Suisse Group AG
2/3/2020WedbushReiterated RatingBuy$237.00Low
i
Rating by Liana Moussatos at Wedbush
1/31/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$116.00 ➝ $120.00Low
i
1/27/2020WedbushReiterated RatingBuy$237.00High
i
Rating by Liana Moussatos at Wedbush
12/15/2019WedbushReiterated RatingBuy$237.00Medium
i
12/10/2019Credit Suisse GroupReiterated RatingBuy$113.00Low
i
Rating by Martin Auster at Credit Suisse Group AG
12/3/2019Bank of AmericaInitiated CoverageUnderperform$80.00High
i
11/1/2019HC WainwrightReiterated RatingHold$85.00Low
i
9/13/2019CowenSet Price TargetHold$118.00Low
i
Rating by Chris Shibutani at Cowen Inc
8/1/2019WedbushReiterated RatingBuy$273.00Low
i
Rating by Liana Moussatos at Wedbush
8/1/2019LADENBURG THALM/SH SHUpgradeNeutral ➝ Buy$103.00 ➝ $106.00High
i
Rating by Matthew Kaplan at LADENBURG THALM/SH SH
8/1/2019Jefferies Financial GroupUpgradeUnderperform ➝ Hold$90.00High
i
7/1/2019Credit Suisse GroupUpgradeNeutral ➝ Outperform$98.00 ➝ $101.00High
i
5/17/2019UBS GroupUpgradeSell ➝ Neutral$115.00 ➝ $94.00Medium
i
5/9/2019Credit Suisse GroupUpgradeUnderperform ➝ Neutral$98.00Medium
i
Rating by Martin Auster at Credit Suisse Group AG
5/8/2019WedbushSet Price TargetBuy$273.00Medium
i
Rating by Liana Moussatos at Wedbush
5/2/2019WedbushBoost Price TargetOutperform ➝ Outperform$269.00 ➝ $273.00High
i
Rating by Liana Moussatos at Wedbush
5/1/2019CowenReiterated RatingHold$103.00High
i
Rating by Chris Shibutani at Cowen Inc
4/9/2019OppenheimerLower Price TargetOutperform$160.00 ➝ $155.00Low
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
4/8/2019WedbushSet Price TargetBuy$269.00High
i
Rating by Liana Moussatos at Wedbush
3/26/2019OppenheimerSet Price TargetBuy$160.00Low
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
3/26/2019Credit Suisse GroupReiterated RatingUnderperform$105.00 ➝ $98.00Medium
i
Rating by Martin Auster at Credit Suisse Group AG
3/19/2019OppenheimerReiterated RatingBuyMedium
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
3/1/2019BarclaysLower Price TargetUnderweight ➝ Underweight$100.00 ➝ $95.00Low
i
2/28/2019LADENBURG THALM/SH SHSet Price TargetHold$124.00Low
i
Rating by Matthew Kaplan at LADENBURG THALM/SH SH
2/27/2019CowenReiterated RatingHold$109.00Low
i
Rating by Chris Shibutani at Cowen Inc
11/20/2018OppenheimerSet Price TargetBuy$160.00Low
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
11/19/2018Credit Suisse GroupBoost Price TargetUnderperform ➝ Sell$103.00 ➝ $105.00Medium
i
Rating by Martin Auster at Credit Suisse Group AG
11/15/2018CowenSet Price TargetHold$106.00High
i
Rating by Chris Shibutani at Cowen Inc
11/2/2018JPMorgan Chase & Co.Boost Price TargetNeutral ➝ Neutral$118.00 ➝ $126.00Low
i
11/1/2018Credit Suisse GroupLower Price TargetUnderperform ➝ Underperform$106.00 ➝ $103.00Low
i
11/1/2018HC WainwrightReiterated RatingHold$95.00High
i
Rating by Andrew Fein at HC Wainwright
10/31/2018CowenSet Price TargetHold$106.00High
i
Rating by Chris Shibutani at Cowen Inc
10/12/2018Standpoint ResearchUpgradeHold ➝ BuyLow
i
9/27/2018WedbushSet Price TargetBuy$253.00High
i
Rating by Liana Moussatos at Wedbush
9/4/2018WedbushSet Price TargetBuy$253.00High
i
Rating by Liana Moussatos at Wedbush
8/13/2018HC WainwrightSet Price TargetHold$95.00Medium
i
Rating by Andrew Fein at HC Wainwright
8/8/2018WedbushSet Price TargetBuy$253.00Low
i
Rating by Liana Moussatos at Wedbush
8/8/2018Credit Suisse GroupDowngradeNeutral ➝ UnderperformLow
i
8/2/2018CowenReiterated RatingHold$110.00Medium
i
8/2/2018BarclaysReiterated RatingSell$100.00High
i
8/2/2018HC WainwrightReiterated RatingHold$95.00High
i
8/2/2018WedbushBoost Price TargetOutperform ➝ Outperform$234.00 ➝ $253.00High
i
7/10/2018Credit Suisse GroupBoost Price TargetNeutral ➝ Neutral$104.00 ➝ $107.00Medium
i
5/3/2018BarclaysLower Price TargetUnderweight ➝ Underweight$105.00 ➝ $95.00Medium
i
5/3/2018Credit Suisse GroupLower Price TargetNeutral ➝ Neutral$108.00 ➝ $104.00Medium
i
4/3/2018Credit Suisse GroupUpgradeUnderperform ➝ Neutral$115.00High
i
2/22/2018BarclaysReiterated RatingUnderweight ➝ Underweight$115.00 ➝ $105.00Low
i
2/22/2018Credit Suisse GroupReiterated RatingUnderperform ➝ Underperform$120.00 ➝ $115.00Medium
i
1/18/2018Credit Suisse GroupReiterated RatingUnderperform ➝ Underperform$118.00Low
i
1/5/2018OppenheimerBoost Price TargetOutperform$180.00Low
i
12/27/2017WedbushReiterated RatingOutperform ➝ Outperform$213.00 ➝ $232.00Medium
i
10/27/2017CowenReiterated RatingHold$129.00N/A
i
10/26/2017HC WainwrightReiterated RatingHold$95.00N/A
i
9/8/2017OppenheimerReiterated RatingBuyLow
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
7/14/2017Jefferies Financial GroupReiterated RatingSell$105.00Low
i
7/6/2017UBS GroupReiterated RatingSell$106.00Low
i
6/8/2017Jefferies Financial GroupReiterated RatingSell$105.00Low
i
4/28/2017Jefferies Financial GroupReiterated RatingUnderperform$116.00 ➝ $105.00Low
i
4/27/2017WedbushReiterated RatingOutperform ➝ Outperform$229.00 ➝ $213.00Low
i
4/26/2017CowenReiterated RatingHold$121.00Low
i
4/17/2017HC WainwrightReiterated RatingHold$95.00Low
i
4/12/2017Jefferies Financial GroupReiterated RatingSell$116.00Low
i
4/11/2017JPMorgan Chase & Co.Set Price TargetHold$125.00Low
i
Rating by Jessica Fye at JPMorgan Chase & Co.
4/4/2017WedbushReiterated RatingOutperform$229.00Low
i
4/3/2017CowenDowngradeOutperform ➝ Market Perform$140.00 ➝ $121.00Low
i
Rating by Chris Shibutani at Cowen Inc
4/3/2017OppenheimerReiterated RatingBuyMedium
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
4/3/2017Credit Suisse GroupReiterated RatingUnderperform$120.00High
i
3/29/2017UBS GroupInitiated CoverageSell ➝ Sell$112.00N/A
i
3/17/2017Jefferies Financial GroupReiterated RatingUnderperform$116.00High
i
3/16/2017Credit Suisse GroupInitiated CoverageUnderperform ➝ Underperform$120.00High
i
3/6/2017Jefferies Financial GroupDowngradeHold ➝ Underperform$149.47 ➝ $116.00N/A
i
2/27/2017WedbushReiterated RatingOutperform$229.00N/A
i
2/23/2017LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral$145.00N/A
i
2/23/2017SVB LeerinkBoost Price TargetMarket Perform$127.00 ➝ $148.00N/A
i
2/22/2017OppenheimerSet Price TargetBuy$160.00 ➝ $175.00N/A
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
2/14/2017OppenheimerReiterated RatingBuyN/A
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
2/8/2017WedbushReiterated RatingOutperform$229.00N/A
i
1/27/2017WedbushReiterated RatingOutperform$229.00N/A
i
1/19/2017Standpoint ResearchDowngradeBuy ➝ HoldN/A
i
1/5/2017WedbushReiterated RatingOutperform$229.00N/A
i
12/14/2016OppenheimerInitiated CoverageOutperform$160.00N/A
i
11/29/2016BarclaysDowngradeEqual Weight ➝ Underweight$115.00 ➝ $100.00N/A
i
11/4/2016WedbushReiterated RatingOutperform$229.00N/A
i
10/28/2016LADENBURG THALM/SH SHUpgradeNeutral ➝ Buy$128.00 ➝ $138.00N/A
i
10/27/2016CowenSet Price TargetBuy$144.00N/A
i
Rating by Chris Shibutani at Cowen Inc
9/23/2016CowenReiterated RatingBuy$144.00N/A
i
Rating by Phil Nadeau at Cowen Inc
8/23/2016ArgusReiterated RatingHoldN/A
i
7/29/2016JPMorgan Chase & Co.Lower Price TargetNeutral$145.00 ➝ $129.00N/A
i
7/29/2016Jefferies Financial GroupReiterated RatingHold$120.00N/A
i
7/29/2016HC WainwrightReiterated RatingHoldN/A
i
Rating by Andrew Fein at HC Wainwright
7/28/2016WedbushReiterated RatingOutperform$229.00N/A
i
Rating by Liana Moussatos at Wedbush
6/15/2016HC WainwrightDowngradeBuy ➝ Neutral$175.00 ➝ $95.00N/A
i
Rating by Andrew Fein at HC Wainwright
5/24/2016ArgusDowngradeBuy ➝ Hold$114.00N/A
i
5/7/2016CowenReiterated RatingOutperform$139.00N/A
i
Rating by Phil Nadeau at Cowen Inc
4/29/2016LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralN/A
i
4/28/2016CowenReiterated RatingBuyN/A
i
Rating by Phil Nadeau at Cowen Inc
4/25/2016WedbushReiterated RatingOutperform$229.00N/A
i
Rating by Liana Moussatos at Wedbush
4/17/2016CowenReiterated RatingBuyN/A
i
Rating by Phil Nadeau at Cowen Inc
4/16/2016SVB LeerinkReiterated RatingMarket PerformN/A
i
4/11/2016Royal Bank of CanadaReiterated RatingSector Perform$150.00 ➝ $122.00N/A
i
3/24/2016WedbushReiterated RatingOutperform$238.00 ➝ $229.00N/A
i
Rating by Liana Moussatos at Wedbush
3/2/2016WedbushLower Price TargetOutperform$244.00 ➝ $238.00N/A
i
Rating by Liana Moussatos at Wedbush
2/28/2016HC WainwrightReiterated RatingBuy$175.00N/A
i
Rating by Andrew Fein at HC Wainwright
2/26/2016Royal Bank of CanadaLower Price TargetSector Perform$175.00 ➝ $150.00N/A
i
2/26/2016SVB LeerinkLower Price TargetMarket Perform$166.00 ➝ $125.00N/A
i
2/26/2016BarclaysLower Price TargetEqual Weight$155.00 ➝ $145.00N/A
i
(Data available from 2/26/2016 forward)
United Therapeutics logo
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and internationally. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma. It also engages in developing OreniPro, RemoPro, Treprostinil Technosphere, Trevyent, Ralinepag, and Aurora-GT to treat PAH; LNG01 to treat IPF; Unexisome to treat BPD; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, biomechanical lungs, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. The company has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder, and Dreamboat and Cricket devices; Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH; and Samumed LLC to develop LNG01. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
Read More

Today's Range

Now: $168.14
$165.98
$170.08

50 Day Range

MA: $168.56
$155.79
$174.85

52 Week Range

Now: $168.14
$75.58
$181.14

Volume

4,430 shs

Average Volume

326,887 shs

Market Capitalization

$7.47 billion

P/E Ratio

15.91

Dividend Yield

N/A

Beta

0.52

Frequently Asked Questions

What sell-side analysts currently cover shares of United Therapeutics?

The following sell-side analysts have issued research reports on United Therapeutics in the last twelve months: Cowen Inc, Credit Suisse Group AG, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., LADENBURG THALM/SH SH, Oppenheimer Holdings Inc., TheStreet, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for UTHR.

What is the current price target for United Therapeutics?

7 Wall Street analysts have set twelve-month price targets for United Therapeutics in the last year. Their average twelve-month price target is $206.86, suggesting a possible upside of 22.8%. Oppenheimer Holdings Inc. has the highest price target set, predicting UTHR will reach $275.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $123.00 for United Therapeutics in the next year.
View the latest price targets for UTHR.

What is the current consensus analyst rating for United Therapeutics?

United Therapeutics currently has 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe UTHR will outperform the market and that investors should add to their positions of United Therapeutics.
View the latest ratings for UTHR.

What other companies compete with United Therapeutics?

How do I contact United Therapeutics' investor relations team?

United Therapeutics' physical mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company's listed phone number is 301-608-9292 and its investor relations email address is [email protected] The official website for United Therapeutics is www.unither.com.